ImmunityBio IBRX
NASDAQ IBRX
$9.44 +0.61 (+6.91%)
As of: Sep 30, 2026 · 3:59 PM EDT

ImmunityBio (IBRX) Current Deferred Revenue (2014 - 2015)

Updated

ImmunityBio (IBRX) recorded Current Deferred Revenue of $235,000 in Q3 2015, down 2.5% from the prior quarter.

Analysis

ImmunityBio (IBRX) Current Deferred Revenue (2014 - 2015) Analysis & Trends

At the end of FY2014, ImmunityBio reported Current Deferred Revenue of $521,000.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 645.01 Bn 563.54 Bn 17.26 Bn
2 AbbVie 465.23 Bn 438.39 Bn 12.70 Bn
3 Merck 368.40 Bn 322.83 Bn 12.21 Bn
4 Novartis Ag 278.02 Bn 233.89 Bn 11.24 Bn
5 Astrazeneca 254.57 Bn 228.13 Bn 12.86 Bn
6 Amgen 229.02 Bn 184.42 Bn 7.24 Bn
7 Gilead Sciences 187.74 Bn 161.85 Bn 6.22 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn
9 Vertex Pharmaceuticals 133.45 Bn 105.45 Bn 2.84 Bn
10 ImmunityBio 9.30 Bn 8.06 Bn 50.94 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2015 235,000.00
Jun 30, 2015 241,000.00
Dec 31, 2014 521,000.00
API Access

ImmunityBio Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=IBRX&period=max&api_key=YOUR_API_KEY